Literature DB >> 21724243

Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease.

Guillaume Geri1, Benjamin Terrier, Michelle Rosenzwajg, Bertrand Wechsler, Maxime Touzot, Danielle Seilhean, Tu-Anh Tran, Bahram Bodaghi, Lucile Musset, Vassili Soumelis, David Klatzmann, Patrice Cacoub, David Saadoun.   

Abstract

BACKGROUND: Behçet disease (BD) is a chronic systemic inflammatory disorder of unknown etiology.
OBJECTIVE: To determine the nature of T cells driving inflammatory lesions in BD.
METHODS: T cell homeostasis and cytokines production were analyzed in peripheral blood and brain inflammatory lesions from 45 adult patients with BD (active and untreated BD [n = 25] and patients in remission [n = 20]) and 20 healthy donors, using Luminex, flow cytometry, immunohistochemistry, and immunofluorescence analysis.
RESULTS: We found a marked increase in T(H)17 cells and a decrease in the frequency of CD4(+) forkhead box P3(+) regulatory T cells (Tregs) in peripheral blood that were induced by IL-21 production and that correlate with BD activity. The addition of serum from patients with active BD in a sorted CD4(+) T cells culture of healthy donors induced a significant and dose-dependent production of IL-17A and a decrease in forkhead box P3 expression. We demonstrated the presence of IL-21- and IL-17A-producing T cells within the cerebrospinal fluid, brain parenchyma inflammatory infiltrates, and intracerebral blood vessels from patients with active BD and central nervous system involvement. The stimulation of CD4(+) T cells with IL-21 increased T(H)17 and T(H)1 differentiation and decreased the frequency of Treg cells. Conversely, IL-21 blockade with an IL-21R-Fc restored the T(H)17 and Treg homeostasis in patients with BD.
CONCLUSION: We provided here the first evidence of the critical role of IL-21 in driving inflammatory lesions in BD by promoting T(H)17 effectors and suppressing Treg cells. IL-21 represents a promising target for novel therapy in BD.
Copyright © 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724243     DOI: 10.1016/j.jaci.2011.05.029

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  69 in total

Review 1.  Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease.

Authors:  Ali Raza; Wajeeha Yousaf; Ralph Giannella; Mohamed Tarek Shata
Journal:  Expert Rev Clin Immunol       Date:  2012-02       Impact factor: 4.473

2.  Cell-cell interaction with APC, not IL-23, is required for naive CD4 cells to acquire pathogenicity during Th17 lineage commitment.

Authors:  Guangpu Shi; Jenna D Lovaas; Cuiyan Tan; Barbara P Vistica; Eric F Wawrousek; Mehak K Aziz; Rachael C Rigden; Rachel R Caspi; Igal Gery
Journal:  J Immunol       Date:  2012-06-27       Impact factor: 5.422

3.  Serum omentin, resistin and tumour necrosis factor-α levels in Behcet patients with and without ocular involvement.

Authors:  Fatih Mehmet Türkcü; Alparslan Şahin; Abdullah Kürşat Cingü; Savaş Kaya; Hatice Yüksel; Yasin Cinar; İbrahim Batmaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-23       Impact factor: 3.117

Review 4.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 5.  Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.

Authors:  Jurgen Sota; Donato Rigante; Giuseppe Lopalco; Bruno Frediani; Rossella Franceschini; Mauro Galeazzi; Florenzo Iannone; Gian Marco Tosi; Claudia Fabiani; Luca Cantarini
Journal:  Rheumatol Int       Date:  2017-07-27       Impact factor: 2.631

6.  Possible association of proinflammatory cytokines including IL1β and TNFα with enhanced Th17 cell differentiation in patients with Behcet's disease.

Authors:  Jun Shimizu; Kenji Takai; Erika Takada; Naruyoshi Fujiwara; Nagisa Arimitsu; Yuji Ueda; Sueshige Wakisaka; Tomoko Suzuki; Noboru Suzuki
Journal:  Clin Rheumatol       Date:  2015-05-14       Impact factor: 2.980

Review 7.  [Behçet's disease - ophthalmological and general aspects part I : etiology, pathogenesis and diagnostics].

Authors:  U Pleyer; D Hazirolan; S Winterhalter; N Stübiger
Journal:  Ophthalmologe       Date:  2012-11       Impact factor: 1.059

8.  Excessive CD4+ T cells co-expressing interleukin-17 and interferon-γ in patients with Behçet's disease.

Authors:  J Shimizu; K Takai; N Fujiwara; N Arimitsu; Y Ueda; S Wakisaka; H Yoshikawa; F Kaneko; T Suzuki; N Suzuki
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

9.  Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet's patients.

Authors:  Cemile Sonmez; Aysegul Atak Yucel; Turan Hilmi Yesil; Hamit Kucuk; Berna Sezgin; Ridvan Mercan; Ahmet Eftal Yucel; Gulderen Yanikkaya Demirel
Journal:  Clin Rheumatol       Date:  2018-03-20       Impact factor: 2.980

10.  Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behçet's disease.

Authors:  Travis Hughes; Filiz Ture-Ozdemir; Fatma Alibaz-Oner; Patrick Coit; Haner Direskeneli; Amr H Sawalha
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.